Results 151 to 160 of about 13,617 (225)

Comparison of the efficacy of different doses of omalizumab (150 mg vs 300 mg) in patients with seasonal allergic rhinitis and low total IgE: A randomized, double-blind, controlled study. [PDF]

World Allergy Organ J
Li L, Xu Y, Bian S, Pan Z, Guan K.
europepmc   +1 more source

Feasibility and Patient Experiences in a WhatsApp‐Based Educational Pilot for Spanish‐Speaking Adults With Chronic Spontaneous Urticaria

International Journal of Dermatology, Volume 65, Issue 6, Page 1285-1287, June 2026.
Elise Edwards, Carlos Lange Nava, Jemima Constanza, Alison Tran, William Abramovits, Gil Yosipovitch   +5 more
wiley   +1 more source

Omalizumab in Dermatology

, 2015
RESUMEN: El omalizumab es un anticuerpo monoclonal ‘humanizado’ que se une selectivamente a IgE libre, inhibiendo su unión a los receptores, tanto el de alta afinidad (FceRI) en la superficie de mastocitos y basófilos, como el de baja afinidad (FceRII ...
Dávila Osorio, Victoria Lucía, Velásquez Lopera, Margarita María   +1 more
core  

Successful Treatment of Refractory Chronic Spontaneous Urticaria with Stapokibart After Omalizumab Failure: A Case Report. [PDF]

Clin Cosmet Investig Dermatol
Chen J, Chen Z, Li X, Chen J, Zhang L, Peng L, Liang B, Chen Q, Li R, Li H, Zhu H.   +10 more
europepmc   +1 more source

Olipudase alfa IgE-mediated anaphylaxis prevented by omalizumab and tailored desensitization in a child with acid sphingomyelinase deficiency. [PDF]

Pediatr Allergy Immunol
Fiori L, Tagi VM, Beretta S, Montanari C, Greco IP, Zuccotti G, D'Auria E.   +6 more
europepmc   +1 more source

The effect of omalizumab treatment on inflammatory parameters in urticarial diseases: a retrospective study. [PDF]

Postepy Dermatol Alergol
Temizel KA, Dursun P, Ikizoglu G.
europepmc   +1 more source

Editorial: A new era in the treatment of food allergy. [PDF]

Front Immunol
Umetsu DT.
europepmc   +1 more source

Toward personalized prediction: a multicenter machine learning model for omalizumab response duration in moderate-to-severe perennial allergic rhinitis. [PDF]

Front Allergy
Miao Z, Dong L, Liu J, Li L, Dong X, Zhang S, Zhu R, Deng Y.   +7 more
europepmc   +1 more source

Rapid food desensitization supported by omalizumab, with adjunctive dupilumab for type 2 comorbidities: A pediatric case series. [PDF]

World Allergy Organ J
Giavina-Bianchi P, Giavina-Bianchi B.
europepmc   +1 more source

A case of eosinophilic dermatosis of hematologic malignancy treated with omalizumab. [PDF]

JAAD Case Rep
Ghanshani R, Chan G, DeClerck B, Kim GH, Crew AB, Lee K, Hsiao JL.   +6 more
europepmc   +1 more source